NCT05491525ClinicalTrials.gov
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
باختصار
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
المرحلة 2 / المرحلة 3مطلوب 71 مشاركاً38 موقعاً16 دولة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT05491525فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2022-08-08; recorded start 2022-10-12
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Participants are not randomly assignedAllocation is recorded as non-randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Urovant Sciences GmbH)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Non-randomised allocation
- Blinding0/20
Open-label
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 38 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study, international in scope: 71 participants (target), run at 38 sites, across 16 countries.
How this score is built
- Enrolment17/40
71 participants (target)
- Site count19/25
38 sites
- Country count15/15
16 countries
- Planned duration10/10
Planned over about 96 months
- Sponsor scale0/10
Urovant Sciences GmbH has led 1 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
الحالات
- Neurogenic Detrusor Overactivity
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 2 Years – 17 Years |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 2 / المرحلة 3 |
| التخصيص | غير معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | NONE (0) |
| التجنيد | مطلوب 71 مشاركاً |
الجهة الراعية والمتعاونون
- Urovant Sciences GmbH الجهة الراعية
- Sumitomo Pharma America, Inc. المتعاونون
الأذرع والتدخلات
- Cohort 1: Weight >=41.5kgEXPERIMENTAL
Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a Data and Safety Monitoring Board (DSMB)-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
- Cohort 2: Weight Range >=29.5 kg to <=41.4 kgEXPERIMENTAL
Part A: participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
- Cohort 3: Weight range >=11 kg to <=29.4 kgEXPERIMENTAL
Part A: Participants will receive a dose of Vibegron based on their weight, with dose reduction based on individual clinical condition, PK, and safety/tolerability data. Participants may be dose-reduced up to 2 times. Part B: Participants will receive a DSMB-selected Vibegron dose for their weight determined from participants in their respective cohort and weight band of Part A.
التدخلات
- دواء Vibegron
Participants will be administered Vibegron orally, once daily (QD)
مقاييس النتائج
مقياس النتيجة الأولي
Change from Baseline in maximum cystometric capacity (MCC) based on bladder filling urodynamics
الإطار الزمني Optimized Treatment Week 24
مقياس النتيجة الثانوي
Change from Baseline in MCC
الإطار الزمني Optimized Week 12
مقياس النتيجة الثانوي
Change from Baseline in number of overactive detrusor contractions until the end of bladder filling
الإطار الزمني Optimized Treatment Weeks 12 and 24
مقياس النتيجة الثانوي
Change from Baseline in detrusor pressure at the end of bladder filling
الإطار الزمني Optimized Treatment Weeks 12 and 24
مقياس النتيجة الثانوي
Change from Baseline in bladder filling volume until first involuntary/hyperactive detrusor contraction
الإطار الزمني Optimized Treatment Weeks 12 and 24
مقياس النتيجة الثانوي
Change from Baseline in bladder compliance (mL/cm H2O)
Bladder compliance is calculated by dividing the change in volume by the change in detrusor pressure during the filling of the bladder
الإطار الزمني Optimized Treatment Weeks 12 and 24
مقياس النتيجة الثانوي
Change from Baseline in average first morning catheterized volume
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in average catheterized volume per catheterization
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in average maximum catheterized volume per day
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in average maximum catheterized daytime volume
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in average number of leakage episodes per day
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in estimated number of dry (leakage-free) days/ 7 days
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in Pediatric Incontinence Questionnaire (PIN-Q)
PIN-Q is a 20-item questionnaire addressing quality of life for participants with bladder disorders. Each question was answered on a scale from 0 (no, never) to 4 (all the time). The total score ranged from 0 to 80, with higher scores indicating more impact on the quality of life.
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in Patient Global Impression of Severity (PGI-S) Scale
PGI-S is a 5 point scale that determines the bladder condition of a participant with 0 being really bad and 4 as really good. Higher score indicates better bladder condition.
الإطار الزمني through study completion, an average of 52 weeks
مقياس النتيجة الثانوي
Change from Baseline in Clinical Global Impression of Change (CGI-C) Scale
The CGI-C scale is used to determine the degree of change in participant's overall bladder symptoms since the start of the study on Day 1. The scale will be filled by the investigator by ticking on any of the following options: very much improved, much improved, minimally improved, no change, minimally worse, much worse and very much worse.
الإطار الزمني through study completion, an average of 52 weeks
التواريخ
| تاريخ البدء | 12 أكتوبر 2022 (فعلي) |
|---|---|
| الإتمام الأولي | 1 مارس 2030 (تقديري) |
| الإتمام | 1 سبتمبر 2030 (تقديري) |
| أول نشر | 8 أغسطس 2022 (فعلي) |
| آخر تحديث | 15 يونيو 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | يونيو 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
32 موقعاً قيد التجنيد
Belgium
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Universitair Ziekenhuis Antwerpen | Edegem | Antwerpen | مسحوب |
| UZ Gent | Ghent | East Flanders | قيد التجنيد |
Canada
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Alberta Children's Hospital | Calgary | Alberta | قيد التجنيد |
| The Hospital for Sick Children | Toronto | Ontario | قيد التجنيد |
Croatia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| University Hospital Split - KBC Split | Split | قيد التجنيد |
Denmark
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Aarhus University Hospital - Department of Paediatrics and Adolescent Medicine | Aarhus | قيد التجنيد |
Georgia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| JSC Evex Hospital M. lashvili Childrens Central Hospital | Tbilisi | قيد التجنيد |
Jordan
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Jordan University Hospital | Amman | قيد التجنيد | |
| Istiklal Hospital | Amman | قيد التجنيد | |
| Irbid Specialty Hospital | Irbid | قيد التجنيد |
Latvia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Childrens Clinical University Hospital | Riga | مسحوب |
Lithuania
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Hospital of Lithuanian University of Health Sciences Kauno klinikos | Kaunas | قيد التجنيد | |
| Vilnius University Hospital Santaros Klinikos | Vilnius | قيد التجنيد |
Malaysia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Kuala Lumpur Hospital | Kuala Lumpur | Kuala Lumpur | قيد التجنيد |
| Hospital Umum Sarawak | Kuching | Sarawak | قيد التجنيد |
Philippines
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| National Children's Hospital | Quezon City | National Capital Region | قيد التجنيد |
Poland
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa | Bialystok | قيد التجنيد | |
| Uniwersyteckie Centrum Kliniczne | Gdansk | قيد التجنيد | |
| Instytut Pomnik - Centrum Zdrowia Dziecka | Warsaw | قيد التجنيد |
Romania
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Institutul Clinic Fundeni | Bucharest | Bucharest | قيد التجنيد |
| Maria Sklodowska Curie Childrens Clinical Emergency Hospital | Bucharest | Bucharest | قيد التجنيد |
Serbia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| University Children's Hospital Tirsova | Belgrade | قيد التجنيد | |
| Children and Youth Health Care Institute of Vojvodina | Novi Sad | قيد التجنيد |
Slovakia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Detská fakultná nemocnica s poliklinikou/Národný ústav detských chorôb (NÚDCH) | Bratislava | قيد التجنيد | |
| Urologická ambulancia J. BREZA MEDICAL s.r.o. | Bratislava | قيد التجنيد |
Turkey (Türkiye)
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Ankara University Faculty of Medicine Ibni Sina Hospital | Ankara | Altindag | قيد التجنيد |
| Mersin University, Dept. of Urology | Yenişehir | قيد التجنيد |
United States
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Albany Medical College | Albany | New York | قيد التجنيد |
| Children's Hospital Colorado | Aurora | Colorado | قيد التجنيد |
| Duke University Medical Center | Durham | North Carolina | أُنهي |
| Nemours Childrens Health, Jacksonville | Jacksonville | Florida | قيد التجنيد |
| Arkansas Childrens Hospital | Little Rock | Arkansas | قيد التجنيد |
| Childrens Hospital New Orleans | New Orleans | Louisiana | مسحوب |
| University of Oklahoma | Oklahoma City | Oklahoma | قيد التجنيد |
| Children's Hospital of Orange County | Orange | California | أُنهي |
| Oregon Health & Science University | Portland | Oregon | مسحوب |
| SUNY Upstate Medical University | Syracuse | New York | قيد التجنيد |
| Wichita Urology Group | Wichita | Kansas | قيد التجنيد |
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
لم تُسجَّل أي تغييرات منذ أن أدرجنا هذا السجل لأول مرة.
يُسجَّل تغيير في كل مرة تحدّث فيها الجهة الراعية سجل السجل. تظهر هنا الحالة والتواريخ والتجنيد والمواقع كلما تغيّرت.